Member Info for Mozax

Is onto something big here.

Ignore the daily movement as this is the type of stock to suddenly disappear over the horizon & buying in will be tricky indeed.

Except The volatility & ignore it, otherwise you’ll be leaving out at the wrong time.

This is the sort of Company that will be bought out for a significant sum.

This has a different feel to it today.

5.5p paid and about to go.

Seller is down to 150k chunks.

And bid rising fast.

Today may well be the start.

At some point the Market will start looking forward & understand what NFX have with NXP002.

Vaccines etc for stopping Covid19 are currently in favour but with around 15% of Covid19 patients suffering Lung Fibrosis it wont be long before The Market discovers Companies well positioned to address this.

With a current MCap of £22M and the potential of Global sales in a multi Billion pound market it’s simply a question of waiting.

I’m a fisherman & understand the rewards of being patient.

We’ve got more going on now than ever before & the current SP is 18 months in the past.

Why DT may be selling.

He blotted his copybook over our Chinese deal and got booted of the Board when he sold some stock inappropriately.

It wouldn’t surprise me if Dan is in no particular rush to push the NXP002 deal through whilst DT is offloading his stock at silly prices.

Wait until he’s done then press ahead.

I certainly wouldn’t look to announce a transformational deal that effectively lands a big ex director who screwed up with a shed load of cash.

Or just a deal for NXP002?

Promedior Announces Completion of Acquisition by Roche

Feb. 13, 2020

LEXINGTON, Mass., /PRNewswire/ -- Promedior, Inc. today announced the successful completion of its previously announced sale to Roche (SIX: RO, ROG;OTCQX: RHHBY). With this acquisition, Roche obtained full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM-151. Under the terms of the merger agreement, Roche made an upfront cash payment of USD 390 million, with additional contingent payments of up to USD 1 billion to be made based on the achievement of certain predetermined development, regulatory and commercial milestones.

Moving up easily, feels as though our seller has unhitched his carriage.

Toot toot.

Just to maintain the old train analogy.

NXP002 is right in the sweet spot.

In a number of patients.

The article was published in The New Scientist a few months back.

Time2Buy has just posted a new link on the global related issue of Lung Fibrosis following infection by Covid in around 15% of patients.

NFX is a stock the market isn’t aware of right now, but just be a little patient a little longer....,,,,.

And let TilS develop the Nebulizer.

Their product, once ready & distributed via our Royalty partner, BMS, is the only one of its type being developed, and rather than focussing on Covid19, it addresses the inflammatory issues associated with The Cykotine Storm.

This issue isn’t going to disappear and Counties across the World will hold stocks of our Nebuliser as an immediate defense to the threat.

This is a very simple buy & hold imo, and just let it play out.

And then there’s all the other stuff going on here too.

Buy, then bottom drawer.

Hardly.

Dan has completed interview after interview with the most recent in February 2020.

It’s now April 2020.

How often do you need to be told the same thing?

Sentiment will turn in an instant & Suddenly all will be back on track.

As the regulars are aware, Stock will be hard to come by with a transformational deal on the table.

Already.

70p going......

With Numerous Companies, watch the interview.

Constant newsflow incoming here, and as I’ve posted previously, this Company will be bought out pretty quickly by a big player.

There’s simply very little stock.

On the Victory XR website.

Gives an Indication of potential just off this one agreement.

Lots of news to come in this space.

The link to Covid & NFX can’t be ‘ highly premature’ when the the global pandemic is causing Fibrosis of the lungs.

So no, I can’t trust you to work it out.

Alwalid and his colleagues have been assessing CT lung scans of people in Wuhan who have caught the virus. In the first week of infection, before symptoms start to show, signs of inflammation become apparent in the lungs. This spreads from one site in one lung to multiple areas of both lungs in the first few weeks of becoming infected, before it starts to improve.
Read more: Can an N95 face mask protect you from catching the new coronavirus?

“We found some fibrosis [scarring] in the lungs, but we don’t know if that is reversible,” he says. “Is it something that will resolve, or will it stay in the lungs? And what might the consequences be?”
For now, the health advice in most countries is the same – avoid areas experiencing an outbreak, cough or sneeze into tissues before binning them, and wash your hands. It is sound advice for avoiding bugs

I think I need to spell it out.

https://www.newscientist.com/article/2235847-coronavirus-what-are-the-worst-symptoms-and-how-deadly-is-covid-19/

Has enjoyed a 4000%+ rise.

Current Covid19 excitement.

Interestingly, NFX is poised for post Covid19.

The New Scientist featured an article suggesting Covid patients suffered lung fibrosis in post Mortem analysis.

Nuformix currently sits at at Early 2019 prices, very little is priced in.

When the market gets wind of what has been developed here & the ever increasing market growing on a daily basis a Novacyt style rise wouldn’t surprise me in the least.

Let the market join the dots........

Going quickly in 50K chunks.

Something occurring, 5 million volume, 3 hrs to go......

Currently, but a few are finding their way here & the SP is gradually building.

Transformational news ( DG’s words) incoming anytime soon, and we’re languishing at prices 14 months ago.

Watch the type of rise associated with Companies in this sector who land Global deals, and remember NXP002 is at stage 3, a phase associated with Big Pharma.